Results 151 to 160 of about 10,523 (190)

Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration. [PDF]

Front Cardiovasc Med
Adámková V, Vitásková M, Hubáček JA.   +2 more
europepmc   +1 more source

Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations. [PDF]

Eur J Prev Cardiol
Ardissino M, Slob EAW, Reddy RK, Morley AP, Schuermans A, Hill P, Williamson C, Honigberg MC, de Marvao A, Ng FS.   +9 more
europepmc   +1 more source

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection. [PDF]

Case Reports Hepatol
Stüben BO, Hoyer DP, Radunz S, Saner F, Schmidt H, Baba HA, Treckmann JW, Mazilescu LI.   +7 more
europepmc   +1 more source

Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study. [PDF]

Front Endocrinol (Lausanne)
Duan H, Shi Y, Zhang Q, Shi X, Zhang Y, Liu J, Zhang Y.   +6 more
europepmc   +1 more source

Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor. [PDF]

Sci Rep
Pussadhamma B, Wongvipaporn C, Wutthimanop A, Nuinoon M, Porntadavity S, Jeenduang N.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PCSK9 inhibitors for treating hypercholesterolemia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis. PCSK9 inhibitors (PCSK9-i), thanks to their efficacy in reducing LDL-C constitute a further step in the treatment of dyslipidemia and
Pasta A., Cremonini A. L., Pisciotta L., Buscaglia A., Porto I., Barra F., Ferrero S., Brunelli C., Rosa G. M.   +8 more
openaire   +2 more sources

Oral PCSK9 Inhibitors

Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita, Agarwala, Ramsha, Asim, Christie M, Ballantyne   +2 more
openaire   +3 more sources